Quizartinib, a type-II inhibitor binding the DFG-out conformation, demonstrated an OS advantage (31.9 vs 15.1 months) when integrated across induction, consolidation, and continuation therapy in FLT3-ITD AML, introducing a “pathway-maintenance” paradigm (Erba et al., 2023). Here, FLT3 is linked to acute myeloid leukemia.